{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:35:30Z","timestamp":1791858930030,"version":"4.3.4"},"reference-count":55,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Iron overload in transfusion-dependent \u03b2-thalassemia (TDT) generates reactive oxygen species, predisposing to post\u2013hematopoietic stem cell transplant (HSCT) endothelial activation. Abatacept prevents acute graft-versus-host disease (GVHD) by inhibiting CD80\/CD86 on T cells, but CD80 is also expressed on neutrophils. Elevated neutrophil extracellular traps (NETs) at day +14 are associated with thrombotic microangiopathy (TMA) after HSCT, mechanistically linking endothelial activation to complement activation. We wanted to compare post-HSCT survival and incidence of endothelial injury syndromes in children with TDT with and without addition of abatacept to standard GVHD prophylaxis. We performed a retrospective review of children with TDT who underwent HSCT at our center. Patients without abatacept served as controls. A total of 64 children underwent HSCT for TDT. Fifty received abatacept and 14 did not. Acute grade 2 to 4 GVHD was lower in the abatacept cohort (0%) compared with the no-abatacept cohort (35%). Incidence of any endothelial injury syndromes (transplant-associated TMA, sinusoidal obstructive syndrome, posterior reversible encephalopathy, and diffuse alveolar hemorrhage) was lower in the abatacept cohort (16%) compared with no abatacept (64%; P = .0009). Day +14 double-stranded DNA (surrogate of NETs) and soluble c5b-9 were lower in the abatacept cohort than the no-abatacept cohort (P = .04 and P &amp;lt; .001, respectively). All patients in the abatacept cohort had full donor myeloid chimerism and remained transfusion independent at a median last follow-up of 1915 days (range, 266-3464) after HSCT. Thalassemia-free survival was 100% in the abatacept cohort and 71% in the no-abatacept cohort. Addition of abatacept to calcineurin inhibitor\u2013based GVHD prophylaxis resulted in excellent thalassemia-free survival and lower endothelial injury syndromes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017197","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T16:31:11Z","timestamp":1757694671000},"page":"6370-6379","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Abatacept improves posttransplant survival and reduces endothelial injury syndromes in \u03b2-thalassemia major"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-6408","authenticated-orcid":false,"given":"Pooja","family":"Khandelwal","sequence":"first","affiliation":[{"name":"1Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azada","family":"Ibrahimova","sequence":"additional","affiliation":[{"name":"1Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lane","sequence":"additional","affiliation":[{"name":"1Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2056-5167","authenticated-orcid":false,"given":"Michael","family":"Grimley","sequence":"additional","affiliation":[{"name":"1Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[{"name":"1Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonata","family":"Jodele","sequence":"additional","affiliation":[{"name":"1Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"2Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"2025122310012032100_bib1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1749-6632.1985.tb17211.x","article-title":"Marrow transplantation for thalassemia","volume":"445","author":"Thomas","year":"1985","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"2025122310012032100_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJM199002153220701","article-title":"Bone marrow transplantation in patients with thalassemia","volume":"322","author":"Lucarelli","year":"1990","journal-title":"N Engl J Med"},{"issue":"2","key":"2025122310012032100_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2012-04-423822","article-title":"Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan","volume":"120","author":"Bernardo","year":"2012","journal-title":"Blood"},{"key":"2025122310012032100_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1749-6632.2010.05590.x","article-title":"The role of reduced intensity preparative regimens in patients with thalassemia given hematopoietic transplantation","volume":"1202","author":"Bertaina","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"2025122310012032100_bib5","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood-2010-09-306829","article-title":"HLA-matched sibling bone marrow transplantation for beta-thalassemia major","volume":"117","author":"Sabloff","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2025122310012032100_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/03630269.2011.643448","article-title":"A novel alpha-thalassemia frameshift mutation: codon 8 (-C)","volume":"36","author":"Tang","year":"2012","journal-title":"Hemoglobin"},{"issue":"12","key":"2025122310012032100_bib7","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.bbmt.2014.07.016","article-title":"Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification","volume":"20","author":"Anurathapan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2025122310012032100_bib8","doi-asserted-by":"crossref","first-page":"a011825","DOI":"10.1101\/cshperspect.a011825","article-title":"Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia","volume":"2","author":"Lucarelli","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025122310012032100_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1196\/annals.1345.023","article-title":"Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group","volume":"1054","author":"La Nasa","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2025122310012032100_bib10","doi-asserted-by":"crossref","first-page":"e2019030","DOI":"10.4084\/mjhid.2019.030","article-title":"Iron toxicity and hemopoietic cell transplantation: time to change the paradigm","volume":"11","author":"Pilo","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"6","key":"2025122310012032100_bib11","doi-asserted-by":"crossref","first-page":"e38089","DOI":"10.1371\/journal.pone.0038089","article-title":"Vascular endothelial dysfunction in beta-thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NO","volume":"7","author":"Stoyanova","year":"2012","journal-title":"PLoS One"},{"issue":"18","key":"2025122310012032100_bib12","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.12998\/wjcc.v7.i18.2746","article-title":"Sinusoidal obstruction syndrome: a systematic review of etiologies, clinical symptoms, and magnetic resonance imaging features","volume":"7","author":"Zhang","year":"2019","journal-title":"World J Clin Cases"},{"issue":"8","key":"2025122310012032100_bib13","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1161\/ATVBAHA.118.311150","article-title":"Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1\u03b1 and cathepsin G","volume":"38","author":"Folco","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2025122310012032100_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nrd1989","article-title":"Abatacept","volume":"5","author":"Moreland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2025122310012032100_bib15","first-page":"CD007277","article-title":"Abatacept for rheumatoid arthritis","volume":"2009","author":"Maxwell","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2025122310012032100_bib16","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI98793","article-title":"CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates","volume":"128","author":"Watkins","year":"2018","journal-title":"J Clin Invest"},{"issue":"17","key":"2025122310012032100_bib17","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2025122310012032100_bib18","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1016\/S2666-6367(22)00558-9","article-title":"Reduction in neutrophil extracellular traps may contribute to the effect of abatacept on clinical outcomes in pediatric patients undergoing allogeneic hematopoietic stem cell transplant","volume":"28","author":"Ibrahimova","year":"2022","journal-title":"Am Soc Transplant Cell Ther"},{"issue":"11","key":"2025122310012032100_bib19","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles","volume":"24","author":"Renner","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2025122310012032100_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbmt.2005.04.007","article-title":"Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Cutler","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2025122310012032100_bib21","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2025122310012032100_bib22","doi-asserted-by":"crossref","first-page":"931.e1","DOI":"10.1016\/j.jtct.2024.06.020","article-title":"Cyclophosphamide and thiotepa increases risk of transplant-associated thrombotic microangiopathy","volume":"30","author":"Higham","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2025122310012032100_bib23","first-page":"S221","article-title":"Non-myeloablative bone marrow transplant with post-transplant cyclophosphamide plus thiotepa improves donor engraftment in patients with transfusion dependent thalassemia: results of an International Consortium (VGC2)","volume":"26","author":"Patel","year":"2020","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025122310012032100_bib24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/TP.0000000000003327","article-title":"Graft-versus-host disease prophylaxis with abatacept reduces severe acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant for beta-thalassemia major with busulfan, fludarabine, and thiotepa","volume":"105","author":"Khandelwal","year":"2021","journal-title":"Transplantation"},{"issue":"10","key":"2025122310012032100_bib25","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.bbmt.2016.08.001","article-title":"A pharmacokinetic and pharmacodynamic study of maraviroc as acute graft-versus-host disease prophylaxis in pediatric allogeneic stem cell transplant recipients with nonmalignant diagnoses","volume":"22","author":"Khandelwal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2025122310012032100_bib26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"12","key":"2025122310012032100_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2025122310012032100_bib28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3390\/cancers15030680","article-title":"Endothelial dysfunction syndromes after allogeneic stem cell transplantation","volume":"15","author":"Vythoulkas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025122310012032100_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Dandoy","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2025122310012032100_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"2025122310012032100_bib31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2025122310012032100_bib32","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood.2023022526","article-title":"A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA","volume":"143","author":"Jodele","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025122310012032100_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European Society for Blood and Marrow Transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2025122310012032100_bib34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2012-02-412197","article-title":"Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies","volume":"120","author":"Fuchs","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2025122310012032100_bib35","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.bbmt.2013.09.005","article-title":"Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"19","author":"Arai","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2025122310012032100_bib36","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41409-025-02601-6","article-title":"Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation","volume":"60","author":"Ibrahimova","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2025122310012032100_bib37","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3390\/cimb46050288","article-title":"Genetic susceptibility in endothelial injury syndromes after hematopoietic cell transplantation and other cellular therapies: climbing a steep hill","volume":"46","author":"Evangelidis","year":"2024","journal-title":"Curr Issues Mol Biol"},{"issue":"12","key":"2025122310012032100_bib38","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.3324\/haematol.2023.283351","article-title":"Mechanisms of endothelial injury and transplant-associated thrombotic microangiopathy in tandem autologous hematopoietic stem cell transplant for neuroblastoma","volume":"108","author":"Sabulski","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"2025122310012032100_bib39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.pcl.2013.02.007","article-title":"Advances in critical care of the pediatric hematopoietic stem cell transplant patient","volume":"60","author":"Chima","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"2025122310012032100_bib40","doi-asserted-by":"crossref","first-page":"1232621","DOI":"10.3389\/fonc.2023.1232621","article-title":"Diffuse alveolar hemorrhage after hematopoietic cell transplantation- response to treatments and risk factors for mortality","volume":"13","author":"Schoettler","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"2025122310012032100_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/cei.12654","article-title":"Neutrophil extracellular traps can activate alternative complement pathways","volume":"181","author":"Wang","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2025122310012032100_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41423-018-0024-0","article-title":"NETosis, complement, and coagulation: a triangular relationship","volume":"16","author":"de Bont","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"2025122310012032100_bib43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","volume":"130","author":"Gloude","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2025122310012032100_bib44","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood.2023023444","article-title":"Evidence for antigen presentation by human neutrophils","volume":"143","author":"Moffat","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025122310012032100_bib45","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.bvth.2024.100020","article-title":"Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202","volume":"1","author":"Newell","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"2","key":"2025122310012032100_bib46","first-page":"S284","article-title":"Increased incidence of mixed chimerism with theuse of fludarabine\u2014treosulfan based conditioning in patientsundergoing allogeneic stem cell transplantation for thalassaemia major","volume":"21","author":"George","year":"2015","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"2025122310012032100_bib47","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/bmt.2015.171","article-title":"Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases","volume":"50","author":"Slatter","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2025122310012032100_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41409-023-02135-9","article-title":"Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial","volume":"59","author":"Sykora","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2025122310012032100_bib49","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00277-021-04732-4","article-title":"Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major","volume":"101","author":"L\u00fcftinger","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"2025122310012032100_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pcl.2009.11.003","article-title":"Chronic graft-versus-host disease (GVHD) in children","volume":"57","author":"Baird","year":"2010","journal-title":"Pediatr Clin North Am"},{"issue":"25","key":"2025122310012032100_bib51","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025122310012032100_bib52","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2023-186196","article-title":"Combining low-dose post-transplant cyclophosphamide (PTCY) with anti-thymocyte globulin (ATG) for prophylaxis of graft-versus-host disease in alternative-donor hematopoietic stem cell transplantation for \u03b2-thalassemia major","volume":"142","author":"Lu","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2025122310012032100_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype beta-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"2025122310012032100_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2025122310012032100_bib55","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/ejh.13512","article-title":"Changing patterns in the epidemiology of beta-thalassemia","volume":"105","author":"Kattamis","year":"2020","journal-title":"Eur J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6370\/2474735\/blooda_adv-2025-017197-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6370\/2474735\/blooda_adv-2025-017197-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:18:37Z","timestamp":1766503117000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6370\/547244\/Abatacept-improves-posttransplant-survival-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":55,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017197","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,11]]}}}